@sandraturner49 @bogda_koczwara Critical opportunity to help men understand ALL their options, including NO active treatment in some men https://t.co/0SX3zE00py and also to implement modern biomarker-driven registry trials @PCFA @ANZUPtrials https://t.co/8
RT @jazzmanahn: 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer | NEJM https://t.co/YQGj3JRwSa
RT @jazzmanahn: 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer | NEJM https://t.co/YQGj3JRwSa
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer | NEJM https://t.co/YQGj3JRwSa
10 yr prostate cancer followup No treatment = 98.5% survived Side effect- 2x more likely to have had cancer progression Surgery = 99.1% survived Side effect- urine leakage, problems with sex life Radiation = 99.3% survived Side effect- bowel problems
@a_dalpra Sure, but citing one (essentially) hypothesis paper and no clinical evidence in prostate cancer that surgery causes cancer to spread. If that were true, then we wouldn’t see indiscernible Kaplan-Meier lines in PROTECT RCT. https://t.co/JVLTNMvrt
RT @JorgeAugustoGaz: El manejo actual para el cáncer de próstata puede realizarse mediante vigilancia activa, cirugía o radioterapia. Estud…
El manejo actual para el cáncer de próstata puede realizarse mediante vigilancia activa, cirugía o radioterapia. Estudio prospectivo comparativo entra las 3 opciones terapéuticas. Resultados completos en https://t.co/NomUKSNa5z https://t.co/0QgPN5BqB8
Cochrane reviews shows vitamin D supplementation alongside standard asthma medication is likely to reduce severe asthmas attacks https://t.co/JsmL5QgUQ8
Cochrane reviews shows vitamin D supplementation alongside standard asthma medication is likely to reduce severe asthma attacks https://t.co/7Ogi3JMTwH
Active monitoring just as effective as surgery or radiotherapy for prostate cancer in terms of survival rate at 10 years - https://t.co/4J2melFHt0
RT @sebasvignoli: Are we witnessing a #medicalreversal in prostate cancer?.It It could be. Remember also ProtecT trial https://t.co/RK2EkRp…
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer #Oncology https://t.co/2rh17zkbJU
Two of my fav studies this year. Thanks for posting together @PA_Maday https://t.co/cnj57u3SUI
ProtecT Trial 10-year outcomes after management of prostate cancer 1) https://t.co/UK0e43ZE0I 2) https://t.co/2wMfOyQYjP
"10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer" https://t.co/ROkXuJmBMs
RT @IlindelatorreMD: Resultados a 10 años después de la monitorización, cirugía o radioterapia por ca de próstata localizado | NEJM https:/…
Resultados a 10 años después de la monitorización, cirugía o radioterapia por ca de próstata localizado | NEJM https://t.co/Gr5cUmN2JK https://t.co/qAF4JSoA8p
https://t.co/6N8QpgFfEl Monitor, surgery or XRT for localized prostate cancer? No mortality difference at 10 yrs. ProtecT trial
RT @sebasvignoli: Are we witnessing a #medicalreversal in prostate cancer?.It It could be. Remember also ProtecT trial https://t.co/RK2EkRp…
RT @sebasvignoli: Are we witnessing a #medicalreversal in prostate cancer?.It It could be. Remember also ProtecT trial https://t.co/RK2EkRp…
Are we witnessing a #medicalreversal in prostate cancer?.It It could be. Remember also ProtecT trial https://t.co/RK2EkRpYvN
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer — NEJM https://t.co/VC2cPbVX7P
RT @drtomround: @SamMerriel predicting #prostatecancer progression- references protect paper no diff mortality 10yrs f/u https://t.co/kt4G7…
@SamMerriel predicting #prostatecancer progression- references protect paper no diff mortality 10yrs f/u https://t.co/kt4G7vzLbx #CaPRI2017
RT @bendean1979: IMHO high quality studies like this https://t.co/ttmoK2cNH0 hint that comparing countries' survival rates measures confoun…
IMHO high quality studies like this https://t.co/ttmoK2cNH0 hint that comparing countries' survival rates measures confounding over quality
Allows me to post my favorite study. Is there any cancer study with a 100% cancer survival? https://t.co/6HftC78VeB @vinay @DoNoHarmProject https://t.co/rszz67yUOM
Allows me to post my favorite study. Is there any cancer study with a 100% cancer survival? @vinay @DoNoHarmProject https://t.co/6HftC78VeB
Excellent study on watchful waiting & choices 4 Prostate cancer https://t.co/lQcSda2DB1 … with PROMs https://t.co/AKYXzbgWsY … https://t.co/aM0VWVo5RC
Excellent study on watchful waiting & choices 4 Prostate cancer https://t.co/lQcSda2DB1 with PROMs https://t.co/AKYXzbgWsY @pash22 https://t.co/6LELrvirRu
今こそ、あらゆる癌の自然経過を再検証する必要がある。団塊が未来の世代に対してできる唯一のプレゼントはそれしかないんです。 https://t.co/54jTUrHVvs
RT @DrTPShakespeare: ProtectT RCT data once more supports #radiation therapy over surgery when treating #ProstateCancer @sandraturner49 @Ta…
RT @DrTPShakespeare: ProtectT RCT data once more supports #radiation therapy over surgery when treating #ProstateCancer @sandraturner49 @Ta…
#Prostate Testing for Cancer and Treatment (ProtecT) trial https://t.co/Vv3jgrD9JY : 10 year findings in the @NEJM https://t.co/UYiDHZK1Yg
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer — NEJM https://t.co/6Zu81ZW7KK
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
Many of our patients enrolled in this study https://t.co/F7J9E0u90i
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
RT @CSR_Bris: Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.c…
Well done ProtecT Study Group-their paper was shortlisted for BMJ Awards, UK Research Paper 2017. Link to paper - https://t.co/X5I8cngPhy https://t.co/BZiGWzaBPh
RT @joaqmorera: Muy interesante. Se dejan de tratar un grupo pero con seguimiento, de estos requieren tratamiento activo en los 9 primeros…
Muy interesante. Se dejan de tratar un grupo pero con seguimiento, de estos requieren tratamiento activo en los 9 primeros meses el 56% https://t.co/3rK0kMtV30
@joaqmorera perdona, es: active monitoring, radical prostatectomy, and radiotherapy mejor esta referencia https://t.co/06qEmyPUJS.
RT @F1000Prime: Ten years on: reviewing survival outcomes of three treatment arms in #prostatecancer patients #WorldCancerDay https://t.co/…
Ten years on: reviewing survival outcomes of three treatment arms in #prostatecancer patients #WorldCancerDay https://t.co/AFceVeVi3b
$PGNX 44% of patients who were assignd to active monitoring didnt receive radical treatment and avoided side effects https://t.co/aSUPWsGSxh https://t.co/adQUIZCV67
@FicarraVincenzo @uretericbud I do agree (sort off). but major issue is over treatment. long term mortality very low https://t.co/BywtaI5IFX
¿Que hacemos con el cáncer de pròstata? https://t.co/WfpTIwso09
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. https://t.co/2MhUfSYsiX
RT @bibliosalut: Resultats després d 10 anys de monitorització, cirurgia o radioteràpia per càncer de pròstata localitzat https://t.co/lOpW…
Resultats després d 10 anys de monitorització, cirurgia o radioteràpia per càncer de pròstata localitzat https://t.co/lOpWCsldQi https://t.co/yrsrGHHJr8
2016 News of the Year: The PROTECT trial, looking at surgery, radiation or nothing for prostate cancer patients. https://t.co/QunhIGSfxk
RT @QuinteTBristol: Recognition for ProtecT study papers - one of the first trials using qualitative research to support recruitment https:…
RT @QuinteTBristol: Recognition for ProtecT study papers - one of the first trials using qualitative research to support recruitment https:…
RT @QuinteTBristol: Recognition for ProtecT study papers - one of the first trials using qualitative research to support recruitment https:…
RT @fischmd: One of the top 3: prostate-cancer–specific mortality was low irrespective of the tx (surgery, XRT, monitoring) https://t.co/bp…
RT @OfficialNIHR: #NIHR funded #prostatecancer study has been named as an @NEJM notable article of 2016. See the ProtecT trial report: http…
RT @OfficialNIHR: #NIHR funded #prostatecancer study has been named as an @NEJM notable article of 2016. See the ProtecT trial report: http…
RT @QuinteTBristol: Recognition for ProtecT study papers - one of the first trials using qualitative research to support recruitment https:…
RT @fischmd: One of the top 3: prostate-cancer–specific mortality was low irrespective of the tx (surgery, XRT, monitoring) https://t.co/bp…
One of the top 3: prostate-cancer–specific mortality was low irrespective of the tx (surgery, XRT, monitoring) https://t.co/bpSHM49A1M https://t.co/QjuJqbXaKn
Recognition for ProtecT study papers - one of the first trials using qualitative research to support recruitment https://t.co/B2h3EYaH9g
RT @OfficialNIHR: #NIHR funded #prostatecancer study has been named as an @NEJM notable article of 2016. See the ProtecT trial report: http…
RT @OfficialNIHR: #NIHR funded #prostatecancer study has been named as an @NEJM notable article of 2016. See the ProtecT trial report: http…
RT @OfficialNIHR: #NIHR funded #prostatecancer study has been named as an @NEJM notable article of 2016. See the ProtecT trial report: http…
RT @OfficialNIHR: #NIHR funded #prostatecancer study has been named as an @NEJM notable article of 2016. See the ProtecT trial report: http…
RT @OfficialNIHR: #NIHR funded #prostatecancer study has been named as an @NEJM notable article of 2016. See the ProtecT trial report: http…
RT @OfficialNIHR: #NIHR funded #prostatecancer study has been named as an @NEJM notable article of 2016. See the ProtecT trial report: http…
#NIHR funded #prostatecancer study has been named as an @NEJM notable article of 2016. See the ProtecT trial report: https://t.co/xEHNHY4ctz
Prostate cancer treatments ... no difference? https://t.co/oMBNiDO0WS
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized #ProstateCancer— NEJM https://t.co/Ceq6DM0z5q
https://t.co/wwXOubMnCQ @JimCatto follow up for ProTect: look at 15 year outcomes, utilize the banked tissue from the trial #suo16
RT @luisotobajas: La mortalidad del cáncer de próstata localizado a 10 años es 1% independientemente del tratamiento que reciba. https://t.…
Masterly inactivity cheaper and appealing for localized prostate cancer — NEJM https://t.co/kbFOLXwDC0
RT @luisotobajas: La mortalidad del cáncer de próstata localizado a 10 años es 1% independientemente del tratamiento que reciba. https://t.…
No difference in 10 year #prostatecancer specific mortality if treated with active monitoring, radiation or surgery. https://t.co/RoWWC0kPgj
RT @luisotobajas: La mortalidad del cáncer de próstata localizado a 10 años es 1% independientemente del tratamiento que reciba. https://t.…
RT @luisotobajas: La mortalidad del cáncer de próstata localizado a 10 años es 1% independientemente del tratamiento que reciba. https://t.…
RT @luisotobajas: La mortalidad del cáncer de próstata localizado a 10 años es 1% independientemente del tratamiento que reciba. https://t.…
RT @luisotobajas: La mortalidad del cáncer de próstata localizado a 10 años es 1% independientemente del tratamiento que reciba. https://t.…
RT @luisotobajas: La mortalidad del cáncer de próstata localizado a 10 años es 1% independientemente del tratamiento que reciba. https://t.…
RT @luisotobajas: La mortalidad del cáncer de próstata localizado a 10 años es 1% independientemente del tratamiento que reciba. https://t.…
Baja mortalidad del CaP localizado independientemente del tto utilizado. https://t.co/rY1a7Rt3OU
RT @luisotobajas: La mortalidad del cáncer de próstata localizado a 10 años es 1% independientemente del tratamiento que reciba. https://t.…
RT @IntraMednet: La mortalidad del cáncer de próstata localizado a 10 años es 1% independientemente del tratamiento que reciba. https://t.c…
RT @luisotobajas: La mortalidad del cáncer de próstata localizado a 10 años es 1% independientemente del tratamiento que reciba. https://t.…
La mortalidad del cáncer de próstata localizado a 10 años, independientemente del tratamiento, es 1%. https://t.co/UrnIY0JuHY